Abstract Body

The past 10 years have seen rapid advances in mycobacterial diagnostics. Specifically, nucleic acid amplification testing has been validated and widely implemented for both TB diagnosis and for identification of resistance to first and second line anti-TB drugs.

The World Health Organization has recommended use of Xpert MTB/RIF (Xpert) as the initial diagnostic test for TB in high HIV or drug-resistant TB settings, including testing of children and for specific forms of extra-pulmonary TB. Xpert simultaneously detects M. tuberculosis and identifies rifampicin resistance, has excellent specificity and improved sensitivity over smear microscopy for diagnosis of TB, but lacks sufficient sensitivity for use as a rule-out test for HIV-associated TB. Studies assessing the impact of Xpert implementation have shown mixed results, particularly where empiric treatment is common; as such treatment may reduce the impact of Xpert on case detection. The role of Xpert in reducing time to treatment, outcome and transmission of drug-resistant TB is an important area for further research.

Several other genotypic tests are now used for identification of resistance to first and second line anti-TB drugs. These detect the absence of wild-type (sensitive) sequence and/or the presence of known resistance-conferring mutations. Line probe assays are commonly used, however targeted sequencing and whole genome sequencing are likely to be increasingly used as they provide improved specificity and broader mutation detection. Obstacles to the widespread implementation of sequencing include limited data on the genotype-phenotype relationship for many drugs, the lack of ‘plug and play’ pipelines for bioinformatics analysis and cost.

Gaps in the current portfolio of diagnostic tests include highly sensitive tests for the diagnosis of extra-pulmonary TB, TB in children and HIV-associated TB. There is a need for a true point-of-care diagnostic (or triage) test for use in remote, low-resource settings and for more simple and rapid tests for accurate detection of resistance to second-line anti-TB drugs.